Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

M. J. Overman; L. Adam; K. Raghav; J. Wang; B. Kee; D. Fogelman; C. Eng; E. Vilar; R. Shroff; A. Dasari; R. Wolff; J. Morris; E. Karunasena; T. R. Pisanic; N. Azad; S. Kopetz

doi:10.1093/annonc/mdy221

Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

M. J. Overman, L. Adam, K. Raghav, J. Wang, B. Kee, D. Fogelman, C. Eng, E. Vilar, R. Shroff, A. Dasari, R. Wolff, J. Morris, E. Karunasena, T. R. Pisanic, N. Azad, S. Kopetz

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.

Original language	English (US)
Pages (from-to)	495
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdy221
State	Published - Mar 1 2019
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy221

Fingerprint

Dive into the research topics of 'Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)'. Together they form a unique fingerprint.

Cite this

Overman, M. J., Adam, L., Raghav, K., Wang, J., Kee, B., Fogelman, D., Eng, C., Vilar, E., Shroff, R., Dasari, A., Wolff, R., Morris, J., Karunasena, E., Pisanic, T. R., Azad, N., & Kopetz, S. (2019). Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688). Annals of Oncology, 30(3), 495. https://doi.org/10.1093/annonc/mdy221

Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688). / Overman, M. J.; Adam, L.; Raghav, K. et al.
In: Annals of Oncology, Vol. 30, No. 3, 01.03.2019, p. 495.

Research output: Contribution to journal › Comment/debate › peer-review

Overman, MJ, Adam, L, Raghav, K, Wang, J, Kee, B, Fogelman, D, Eng, C, Vilar, E, Shroff, R, Dasari, A, Wolff, R, Morris, J, Karunasena, E, Pisanic, TR, Azad, N & Kopetz, S 2019, 'Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)', Annals of Oncology, vol. 30, no. 3, pp. 495. https://doi.org/10.1093/annonc/mdy221

@article{54fd6452821f4c3a8e1674c75575586f,

title = "Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)",

abstract = "In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.",

author = "Overman, {M. J.} and L. Adam and K. Raghav and J. Wang and B. Kee and D. Fogelman and C. Eng and E. Vilar and R. Shroff and A. Dasari and R. Wolff and J. Morris and E. Karunasena and Pisanic, {T. R.} and N. Azad and S. Kopetz",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].",

year = "2019",

month = mar,

day = "1",

doi = "10.1093/annonc/mdy221",

language = "English (US)",

volume = "30",

pages = "495",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Corrigendum

T2 - Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

AU - Overman, M. J.

AU - Adam, L.

AU - Raghav, K.

AU - Wang, J.

AU - Kee, B.

AU - Fogelman, D.

AU - Eng, C.

AU - Vilar, E.

AU - Shroff, R.

AU - Dasari, A.

AU - Wolff, R.

AU - Morris, J.

AU - Karunasena, E.

AU - Pisanic, T. R.

AU - Azad, N.

AU - Kopetz, S.

N1 - Publisher Copyright: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].

PY - 2019/3/1

Y1 - 2019/3/1

N2 - In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.

AB - In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85064122501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064122501&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy221

DO - 10.1093/annonc/mdy221

M3 - Comment/debate

C2 - 29982323

AN - SCOPUS:85064122501

SN - 0923-7534

VL - 30

SP - 495

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this